Robert S. Kania

5.7k citations

23 papers · 2.4k indexed · 3 hit papers · h-index 16

Impact in

Organic Chemistry top 2%
- Click Chemistry and Applications
- Synthesis and biological activity
- Carbohydrate Chemistry and Synthesis
Molecular Biology top 5%
- Chemical Synthesis and Analysis
- Angiogenesis and VEGF in Cancer

Papers in

Molecular Biology 19
- PI3K/AKT/mTOR signaling in cancer 5
- Chemical Synthesis and Analysis 4
- Melanoma and MAPK Pathways 3
- Angiogenesis and VEGF in Cancer 3
- Fibroblast Growth Factor Research 2
Oncology 5

Co-authors: E. J. Corey Michele McTigue Brion W. Murray Jeffrey H. Chen Charles K. Marlowe David Y. Gin Ronald N. Zuckermann James Solowiej
Journals: Journal of the American Chemical Society (4 papers)Journal of Medicinal Chemistry (4 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)Tetrahedron Letters (2 papers)Proceedings of the National Academy of Sciences (2 papers)
Partner nations: United States Italy

In The Last Decade

Robert S. Kania

22 papers receiving 2.4k citations

Hit Papers

align trajectories log scale

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors 2012 · 451 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 Proceedings of the National Academy of Sciences
2008 Clinical Cancer Research
1992 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Robert S. Kania

Since Specialization

Citations

This map shows the geographic impact of Robert S. Kania's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert S. Kania with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert S. Kania more than expected).

Fields of papers citing papers by Robert S. Kania

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert S. Kania. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert S. Kania. The network helps show where Robert S. Kania may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert S. Kania, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert S. Kania Line = papers co-authored together Robert S. Kania links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Discovery of KIN-8741, a Highly Selective Type IIb c-Met Kinase Inhibitor with Broad Mutation Coverage and Quality Drug-Like Properties for the Treatment of Cancer Journal of Medicinal Chemistry ·Xiaohu Ouyang, Kathryn B. Grandinetti, Mats Borén, Subhas J. Chakravorty, Mian Muhammad Ahmed Shah, Ping Jiang, Toufike Kanouni, Tatiana Koudriakova, Siti Kulashatul Wafiyyah, Carol Jo Charles, Michelle Salazar Pérez, Rowena Suriben, Anderson Mojica, Sanjeev Thohan, Sean Uryu, HarryF . Martz, Yuan Ding, Robert S. Kania, Jason M. Cox	2025	0
2	The Discovery of Exarafenib (KIN-2787): Overcoming the Challenges of Pan-RAF Kinase Inhibition Journal of Medicinal Chemistry ·Young K. Chen, Toufike Kanouni, Lee D. Arnold, Jason M. Cox, Elisabeth Gardiner, Kathryn B. Grandinetti, Ping Jiang, Stephen W. Kaldor, Catherine Lee, Chun Li, Eric S. Martin, Nichol Miller, Eric A. Murphy, Anderson Mojica, John Tyhonas, N. Tsopelas, Zhenyu Fan, Richard Williams, Yuan Ding, Robert S. Kania	2024	5
3	Cross Contamination during Simulated Food Pantry Handling of Apples, Oranges and Potatoes Journal of Food Research ·Paul A. Dawson, W D W, J.K. Northcutt, LI Jiangxue, Isabel Cristina Gomes Basoni, Adriana María Londoño Jaramillo, Kimberly Hendershot, Karima Zerguini, Robert S. Kania, Michael Leahy, Saito Tsunehiro, andi achmad gazali, Sung-Jin Huh, M. Strickland, Ann Thomas	2023	1
4	Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations. Journal of Clinical Oncology ·Aleksandra Franovic, W Ziyada, Sean Uryu, Qibiao Wu, Ping Jiang, Nichol Miller, John Tyhonas, Oleksandr Sautin, Paul Severson, Robert S. Kania, Eric A. Murphy, Nabeel Bardeesy, Eric S. Martin	2022	7
5	Multiple conformational states of the HPK1 kinase domain in complex with sunitinib reveal the structural changes accompanying HPK1 trans-regulation Journal of Biological Chemistry ·Eric F. Johnson, Michele McTigue, Rebecca A. Gallego, Ted W. Johnson, Sergei Timofeevski, Waluyanti Sri, Timothy S. Fisher, Robert S. Kania, Sansana Sawasdikosol, Steven J. Burakoff, Ciarán N. Cronin	2019	21
6	Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers PLoS ONE ·Luping Qiu, Kymberly K. Levine, K.S. Gajiwala, Ciarán N. Cronin, Asako Nagata, Eric F. Johnson, Michelle L. Kraus, John Tatlock, Robert S. Kania, Timothy L. Foley, Shaoxian Sun	2018	16
7	Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series Bioorganic & Medicinal Chemistry Letters ·Hengmiao Cheng, Jacqui Hoffman, Phuong Le, Mason Pairish, Robert S. Kania, William Farrell, Shubha Bagrodia, Jing Yuan, Shaoxian Sun, Eric Zhang, Wang Hong-pin, Deepak Dalvie, Sadayappan V. Rahavendran	2013	23
8	Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors Proceedings of the National Academy of Sciences ·Michele McTigue, Brion W. Murray, Jeffrey H. Chen, Yali Deng, James Solowiej, Robert S. Kania Hit paper breakdown →	2012	451
9	Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug–drug interaction Bioorganic & Medicinal Chemistry Letters ·Cynthia L. Palmer, Mason Pairish, Susan E. Kephart, Djamal Bouzida, Jingrong Jean Cui, Judith G. Deal, Liming Dong, Aurelia Genco, Angelica Linton, Indrawan McAlpine, Shinji Yamazaki, Evan Smith, Muhammad Aasim Ullah, Shubha Bagrodia, Robert S. Kania, Chuangxing Guo	2012	3
10	Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone Bioorganic & Medicinal Chemistry Letters ·Pei‐Pei Kung, Jamoliddin Yodgorov, Paul Richardson, Michael J. Hickey, K.S. Gajiwala, Fen Wang, Buwen Huang, LR Nayak, Jeff Wang, Karen A. Maegley, Simon Bergqvist, Pramod P. Mehta, Robert S. Kania	2011	35
11	Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design MedChemComm ·Hengmiao Cheng, Shubha Bagrodia, Simon Bailey, Martin P. Edwards, Jacqui Hoffman, Qiyue Hu, Robert S. Kania, Daniel R. Knighton, Matthew A. Marx, Sacha Ninkovic, Shaoxian Sun, Eric Zhang	2010	57
12	Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 Clinical Cancer Research ·Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini, Max Hallin, Grant Wickman, Karin Amundson, Jeffrey H. Chen, David A. Rewolinski, Shinji Yamazaki, Xinglin Wu, Michele McTigue, Brion W. Murray, Robert S. Kania, Patrick M. O’Connor, David R. Shalinsky, Steve Bender Hit paper breakdown →	2008	515
13	Structure-Based Design of (5-Arylamino-2H-pyrazol-3-yl)-biphenyl-2‘,4‘-diols as Novel and Potent Human CHK1 Inhibitors Journal of Medicinal Chemistry ·Min Teng, JinJiang Zhu, Michael D. Johnson, Ping Chen, Hamid Zafari-Koloukhi, Enhong Chen, Alessandra Blasina, James Register, Kenna Anderes, Bob Hey, Ya‐Li Deng, Sacha Ninkovic, Stephan K. Grant, Qiyue Hu, Karen Lundgren, Zhengwei Peng, Robert S. Kania	2007	28
14	AG-028262, a novel selective VEGFR tyrosine kinase antagonist that potently inhibits KDR signaling and angiogenesis in vitro and in vivo Cancer Research ·Helen Y. Zou, Qiuhua Li, Maren L. Grazzini, A Heijne von, Karin Amundson, Jake Schutzman, Grant Wickman, Mehdi Gholizadeh, 光陈, Scott Jacobs, 公平河野, Brion W. Murray, Michele McTigue, R. Pagán, Jihong Lou, David C. Gale, Steve Bender, Robert S. Kania, David R. Shalinsky, Dana D. Hu‐Lowe	2004	7
15	Concise total synthesis of (±)-palominol and (±)-dolabellatrienone via a dianion-accelerated oxy-cope rearrangement Tetrahedron Letters ·E. J. Corey, Robert S. Kania	1998	23
16	First Enantioselective Total Synthesis of a Naturally Occurring Dolabellane. Revision of Absolute Configuration Journal of the American Chemical Society ·E. J. Corey, Robert S. Kania	1996	47
17	Free C-Terminal Resin-Bound Peptides: Reversal of Peptide Orientation via A Cyclization/Cleavage Protocol Journal of the American Chemical Society ·Robert S. Kania, Ronald N. Zuckermann, Charles K. Marlowe	1994	25
18	Studies on the total synthesis of lactacystin. An improved aldol coupling reaction and a β-lactone intermediate in thiol ester formation Tetrahedron Letters ·E. J. Corey, Gregory A. Reichard, Robert S. Kania	1993	43
19	Peptoids: a modular approach to drug discovery. Proceedings of the National Academy of Sciences ·Reyna J. Simon, Robert S. Kania, Ronald N. Zuckermann, Verena D. Huebner, David A. Jewell, Steven C. Banville, Simon Ng, J E Carter, David Leong, Charles K. Marlowe Hit paper breakdown →	1992	772
20	Efficient method for regioselective isoprenylation of cysteine thiols in unprotected peptides Journal of the American Chemical Society ·Chi Ching Yang, Charles K. Marlowe, Robert S. Kania	1991	31

About Robert S. Kania

Robert S. Kania is a scholar working on Molecular Biology, Oncology, Pharmacology, Organic Chemistry and Microbiology, having authored 23 papers that have together received 2.4k indexed citations. Recurring topics across this work include PI3K/AKT/mTOR signaling in cancer (5 papers), Chemical Synthesis and Analysis (4 papers), Microbial Natural Products and Biosynthesis (3 papers), Melanoma and MAPK Pathways (3 papers), Angiogenesis and VEGF in Cancer (3 papers), Cancer Mechanisms and Therapy (2 papers), Renal cell carcinoma treatment (2 papers) and Fibroblast Growth Factor Research (2 papers). The work is most often cited by research in Organic Chemistry (908 citations), Molecular Biology (1.6k citations), Cancer Research (341 citations), Microbiology (116 citations) and Biotechnology (155 citations). Robert S. Kania has collaborated with scholars based in United States and Italy. Frequent co-authors include E. J. Corey, Michele McTigue, Brion W. Murray, Jeffrey H. Chen, Charles K. Marlowe, David Y. Gin, Ronald N. Zuckermann, James Solowiej, Reyna J. Simon and David A. Jewell. Their work appears in journals such as Journal of the American Chemical Society, Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, Tetrahedron Letters and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact